Last reviewed · How we verify
EVO301
EVO301 is a monoclonal antibody targeting CD22.
EVO301 is a monoclonal antibody targeting CD22. Used for Relapsed or refractory B-cell acute lymphoblastic leukemia.
At a glance
| Generic name | EVO301 |
|---|---|
| Sponsor | Evommune, Inc. |
| Drug class | CD22-targeting monoclonal antibody |
| Target | CD22 |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
EVO301 works by binding to CD22 on the surface of B cells, leading to their depletion and potentially reducing B cell-mediated immune responses.
Approved indications
- Relapsed or refractory B-cell acute lymphoblastic leukemia
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |